Jennifer Ann Johnson, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Penicillin G Benzathine | 1 | 2018 | 25 | 0.620 |
Why?
|
| AIDS Vaccines | 5 | 2018 | 900 | 0.590 |
Why?
|
| Syphilis | 1 | 2018 | 243 | 0.500 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2014 | 39 | 0.470 |
Why?
|
| Endocarditis, Bacterial | 2 | 2020 | 436 | 0.430 |
Why?
|
| Nasal Cavity | 1 | 2014 | 311 | 0.410 |
Why?
|
| Anti-Bacterial Agents | 7 | 2020 | 7478 | 0.400 |
Why?
|
| Encephalitis, Viral | 1 | 2012 | 59 | 0.390 |
Why?
|
| HIV-2 | 1 | 2012 | 156 | 0.380 |
Why?
|
| Endocarditis | 4 | 2020 | 352 | 0.380 |
Why?
|
| Actinomycetales | 1 | 2011 | 33 | 0.370 |
Why?
|
| Actinomycetales Infections | 1 | 2011 | 30 | 0.370 |
Why?
|
| Rheumatic Heart Disease | 1 | 2012 | 164 | 0.360 |
Why?
|
| Carrier State | 1 | 2014 | 529 | 0.360 |
Why?
|
| Drug Carriers | 3 | 2018 | 710 | 0.360 |
Why?
|
| Pleurisy | 1 | 2011 | 54 | 0.360 |
Why?
|
| Bacteremia | 3 | 2020 | 985 | 0.340 |
Why?
|
| Foot Diseases | 1 | 2010 | 148 | 0.310 |
Why?
|
| HIV Infections | 9 | 2018 | 17591 | 0.310 |
Why?
|
| Propionates | 1 | 2009 | 180 | 0.310 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 704 | 0.300 |
Why?
|
| Adenoviruses, Human | 3 | 2014 | 257 | 0.290 |
Why?
|
| Anti-HIV Agents | 3 | 2013 | 4576 | 0.280 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2012 | 641 | 0.280 |
Why?
|
| Acidosis | 1 | 2009 | 271 | 0.280 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2022 | 3683 | 0.270 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2014 | 1903 | 0.260 |
Why?
|
| Genetic Vectors | 3 | 2018 | 3412 | 0.250 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2020 | 530 | 0.250 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 6086 | 0.250 |
Why?
|
| Anti-Retroviral Agents | 1 | 2014 | 1795 | 0.240 |
Why?
|
| Thromboembolism | 1 | 2010 | 1004 | 0.210 |
Why?
|
| Ebstein Anomaly | 1 | 2022 | 106 | 0.190 |
Why?
|
| Bone Diseases, Infectious | 1 | 2020 | 16 | 0.180 |
Why?
|
| Sternotomy | 1 | 2021 | 132 | 0.180 |
Why?
|
| HIV-1 | 6 | 2018 | 6962 | 0.180 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2021 | 156 | 0.170 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 1665 | 0.150 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2022 | 362 | 0.150 |
Why?
|
| Treatment Refusal | 1 | 2020 | 433 | 0.130 |
Why?
|
| Fatal Outcome | 3 | 2010 | 1836 | 0.130 |
Why?
|
| Doxycycline | 1 | 2018 | 349 | 0.130 |
Why?
|
| Contact Tracing | 1 | 2018 | 275 | 0.130 |
Why?
|
| Staphylococcal Infections | 3 | 2012 | 1398 | 0.130 |
Why?
|
| Buprenorphine | 2 | 2020 | 667 | 0.120 |
Why?
|
| Heart Defects, Congenital | 1 | 2012 | 4712 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 6401 | 0.120 |
Why?
|
| Opiate Substitution Treatment | 1 | 2020 | 452 | 0.120 |
Why?
|
| Opioid-Related Disorders | 2 | 2020 | 2188 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 2 | 2010 | 5443 | 0.120 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 4363 | 0.120 |
Why?
|
| Hospitals, Urban | 2 | 2014 | 499 | 0.120 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2014 | 45 | 0.120 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2014 | 381 | 0.110 |
Why?
|
| Canarypox virus | 1 | 2013 | 10 | 0.110 |
Why?
|
| Orthopoxvirus | 1 | 2013 | 10 | 0.110 |
Why?
|
| Neck | 1 | 2018 | 736 | 0.110 |
Why?
|
| Viridans Streptococci | 1 | 2012 | 16 | 0.100 |
Why?
|
| Surgical Wound Infection | 1 | 2021 | 1547 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1088 | 0.100 |
Why?
|
| Toes | 2 | 2010 | 209 | 0.100 |
Why?
|
| Minnesota | 1 | 2012 | 339 | 0.100 |
Why?
|
| Gene Products, env | 1 | 2012 | 250 | 0.100 |
Why?
|
| Brain Abscess | 1 | 2012 | 123 | 0.090 |
Why?
|
| Immunity, Mucosal | 1 | 2014 | 498 | 0.090 |
Why?
|
| Capsid Proteins | 1 | 2014 | 468 | 0.090 |
Why?
|
| Brain | 4 | 2012 | 27453 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 13021 | 0.090 |
Why?
|
| Ritonavir | 1 | 2012 | 332 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 236 | 0.090 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2012 | 1048 | 0.090 |
Why?
|
| DNA, Ribosomal | 1 | 2011 | 300 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2020 | 2701 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2020 | 2784 | 0.080 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2012 | 342 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 328 | 0.080 |
Why?
|
| Adenoviridae | 1 | 2013 | 1095 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2012 | 2598 | 0.080 |
Why?
|
| Methicillin Resistance | 2 | 2006 | 198 | 0.080 |
Why?
|
| Staphylococcus aureus | 2 | 2006 | 1430 | 0.080 |
Why?
|
| Infarction | 1 | 2010 | 247 | 0.080 |
Why?
|
| Viral Load | 3 | 2012 | 3398 | 0.080 |
Why?
|
| Vaccines, Synthetic | 3 | 2018 | 622 | 0.080 |
Why?
|
| Blood | 1 | 2011 | 599 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 1340 | 0.080 |
Why?
|
| Fontan Procedure | 1 | 2014 | 805 | 0.070 |
Why?
|
| Humans | 27 | 2022 | 768970 | 0.070 |
Why?
|
| Streptococcal Infections | 1 | 2012 | 619 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2012 | 888 | 0.070 |
Why?
|
| Oxacillin | 1 | 2006 | 41 | 0.070 |
Why?
|
| Fingers | 1 | 2010 | 512 | 0.070 |
Why?
|
| Medical Records | 1 | 2012 | 1411 | 0.070 |
Why?
|
| Thrombosis | 1 | 2020 | 2956 | 0.070 |
Why?
|
| Patient Discharge | 1 | 2020 | 3491 | 0.070 |
Why?
|
| Adenine | 1 | 2012 | 995 | 0.070 |
Why?
|
| Embolism | 1 | 2009 | 401 | 0.070 |
Why?
|
| Male | 16 | 2020 | 365203 | 0.070 |
Why?
|
| Basal Ganglia | 1 | 2009 | 555 | 0.060 |
Why?
|
| DNA, Bacterial | 1 | 2011 | 1478 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2012 | 2089 | 0.060 |
Why?
|
| Microscopy | 1 | 2011 | 910 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 4862 | 0.060 |
Why?
|
| Antigen Presentation | 1 | 2010 | 1252 | 0.060 |
Why?
|
| Middle Aged | 12 | 2020 | 223737 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2011 | 1321 | 0.060 |
Why?
|
| RNA, Viral | 1 | 2012 | 2871 | 0.060 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2010 | 1096 | 0.050 |
Why?
|
| Treatment Outcome | 7 | 2022 | 65480 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2012 | 20776 | 0.050 |
Why?
|
| Retrospective Studies | 7 | 2020 | 81903 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2006 | 472 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2014 | 2192 | 0.050 |
Why?
|
| HIV Antibodies | 3 | 2014 | 1341 | 0.050 |
Why?
|
| Vision Disorders | 1 | 2010 | 1093 | 0.050 |
Why?
|
| Placebos | 2 | 2018 | 1667 | 0.050 |
Why?
|
| Bone Wires | 1 | 2021 | 125 | 0.050 |
Why?
|
| Adult | 10 | 2020 | 223851 | 0.050 |
Why?
|
| Gene Expression | 1 | 2014 | 7603 | 0.050 |
Why?
|
| Ischemia | 1 | 2010 | 1900 | 0.050 |
Why?
|
| Sternum | 1 | 2021 | 177 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 4785 | 0.040 |
Why?
|
| Echocardiography | 1 | 2012 | 5047 | 0.040 |
Why?
|
| Tricuspid Valve | 1 | 2022 | 419 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 14752 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2012 | 36854 | 0.040 |
Why?
|
| Bone Plates | 1 | 2021 | 468 | 0.040 |
Why?
|
| Weight Loss | 1 | 2010 | 2721 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 17629 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 15471 | 0.040 |
Why?
|
| Female | 11 | 2020 | 397515 | 0.040 |
Why?
|
| Pulmonary Circulation | 1 | 2020 | 744 | 0.040 |
Why?
|
| Vaccines, Subunit | 1 | 2018 | 159 | 0.040 |
Why?
|
| Catheters | 1 | 2020 | 427 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 8055 | 0.040 |
Why?
|
| Methadone | 1 | 2020 | 317 | 0.040 |
Why?
|
| Naltrexone | 1 | 2020 | 319 | 0.040 |
Why?
|
| Young Adult | 5 | 2018 | 60131 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 3813 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2014 | 41808 | 0.030 |
Why?
|
| Double-Blind Method | 3 | 2018 | 12467 | 0.030 |
Why?
|
| Injections | 1 | 2020 | 841 | 0.030 |
Why?
|
| Vaccinia virus | 1 | 2018 | 330 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2014 | 1855 | 0.030 |
Why?
|
| Heart Failure | 1 | 2020 | 11879 | 0.030 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 591 | 0.030 |
Why?
|
| Child | 3 | 2014 | 80960 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15951 | 0.030 |
Why?
|
| Liver | 1 | 2010 | 7578 | 0.030 |
Why?
|
| Analgesics, Opioid | 2 | 2020 | 3838 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2018 | 610 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2014 | 126 | 0.030 |
Why?
|
| Infant | 2 | 2014 | 36556 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2014 | 556 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2014 | 42683 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2021 | 1682 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 1560 | 0.030 |
Why?
|
| Risk Factors | 3 | 2021 | 74976 | 0.020 |
Why?
|
| Propionibacterium acnes | 1 | 2012 | 59 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2012 | 26428 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 1945 | 0.020 |
Why?
|
| Adolescent | 4 | 2014 | 89244 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 146 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 223 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 140 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 54962 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 328 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8559 | 0.020 |
Why?
|
| Cryoglobulinemia | 1 | 2009 | 84 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5323 | 0.020 |
Why?
|
| Hemianopsia | 1 | 2009 | 121 | 0.020 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2009 | 167 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2009 | 344 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2020 | 9684 | 0.020 |
Why?
|
| Hospitalization | 1 | 2006 | 10847 | 0.020 |
Why?
|
| Colon | 1 | 2014 | 1803 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2020 | 3313 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2009 | 1609 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 2006 | 277 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 1716 | 0.010 |
Why?
|
| Haplotypes | 1 | 2010 | 2725 | 0.010 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 2009 | 0.010 |
Why?
|
| Shock | 1 | 2006 | 316 | 0.010 |
Why?
|
| Aged | 2 | 2014 | 171786 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2014 | 3044 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2010 | 3956 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 2006 | 657 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 6320 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 14794 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 4413 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2006 | 1159 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 169335 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2010 | 5404 | 0.010 |
Why?
|
| Survival Rate | 1 | 2014 | 12873 | 0.010 |
Why?
|
| Alleles | 1 | 2010 | 6901 | 0.010 |
Why?
|
| Cytokines | 1 | 2014 | 7453 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2010 | 3080 | 0.010 |
Why?
|
| Cross Infection | 1 | 2006 | 1425 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 4651 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2009 | 6413 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 13318 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 13674 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 12095 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2006 | 5369 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12801 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 16053 | 0.010 |
Why?
|
| Age Factors | 1 | 2006 | 18435 | 0.010 |
Why?
|
| Incidence | 1 | 2006 | 21547 | 0.000 |
Why?
|
| Time Factors | 1 | 2006 | 40261 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2006 | 59739 | 0.000 |
Why?
|